CSIR in the news..

An aggregation of news on the web about CSIR and its laboratories

Archive for the ‘IMTECH’ Category

‘Indian industry should trust scientists’: Institute of Microbial Technology head

09 February 2011

Experts gathered at a programme on ‘Harnessing Intellectual Property for Strategic Competitive and Collaborative Advantage’ at Indian Institute of Management, Ahmedabad (IIMA) on Tuesday believe that it is time for an alliance between industries and academic institutions. Director, Institute of Microbial Technology (IMTECH), Chandigarh Dr Girish Sahni who is credited with two major licensing deals in the pharma sector, delivered the keynote address at the event…..

Read more: http://www.dnaindia.com/india/report_indian-industry-should-trust-scientists-institute-of-microbial-technology-head_1505408

Written by csirindia

February 9, 2011 at 9:38 pm

Posted in IMTECH

Seminar on academia tie-up with India Inc

09 February 2011

AHMEDABAD: A lecture on Intellectual Property Rights (IPR) and biotechnology by a top Indian scientist turned into a brainstorming session at IIM-Ahmedabad on Tuesday.

“Ultimately, we would like Indian industry to tie-up with Indian institutions,” said Girish Sahni, director of the CSIR-funded Institute of Microbial Technology (IMTECH) at Chandigarh, which had developed the third and fourth generation thrombolytic molecules eventually licensed to a US firm for 150 million dollars recently. He was speaking at the seminar on stagnant Indian Industry- Indian academia linkage……..

Read more: http://www.indianexpress.com/news/seminar-on-academia-tieup-with-india-inc/747851/

Written by csirindia

February 9, 2011 at 9:35 pm

Posted in IMTECH

Bio-pharmaceutical lab for IMTECH

25 January 2011

The Institute of Microbial Technology (IMTECH), a part of the Council for Scientific and Industrial Research (CSIR), today got a bio-pharmaceutical laboratory, which is a one-of-its kind in the public sector. Union Science & Technology Minister Pawan Kumar Bansal inaugurated the facility at the IMTECH premises in Sector 39, Chandigarh.

The laboratory has the facility of microfiltration, centrifuge and ultra-filtration. It is meant for drug purification, which will increase the remuneration value during the transfer of technology. The facility is yet to get Current Good Manufacturing Practice (CGMP) certification, which is a global standard used in the manufacture of pharmaceuticals, food and medical devices.

Speaking at the function, which also marked the Institute’s foundation day, IMTECH Director Girish Sahni said, “We have ploughed back the money earned through transfer of technology into the laboratory.” CSIR Director General S K Brahmchari said, “IMTECH is a small precious stone which sits on the crown of CSIR. It has shown how it can glitter and do that for which it was established.”

Read more: http://www.indianexpress.com/news/Bio-pharmaceutical-lab-for-IMTECH/741806/

Written by csirindia

January 26, 2011 at 8:43 am

Posted in IMTECH

Use benefits of science and technology for mankind: Bansal

24 January 2011

CHANDIGARH: (PTI) Innovative researches in science and technology must be used for the greater benefit of mankind, a Union minister said here today.

“Scientists need to learn from our limitations and should try to give the best from the available resources.

They should also be provided new opportunities and incentives for carrying out their work,” Union Minister of Science and Technology and Earth Sciences, Pawan Kumar Bansal said here.

He also inaugurated the new bio-pharmaceutical facility at Institute of Microbial Technology (IMTECH) here on the occasion.

Bansal advised institutes like IMTECH to carry on research for coming up with affordable medicines and vaccines.

Samir K Brahamachari, Director General, Centre for Scientific and Industrial Research (CSIR) spoke on the ”CSIR Vision 2022”.

CSIR with its 39 high-tech extension centres were playing an important role for changing the face of science and technology sector in India, he said.

Source: http://news.in.msn.com/national/article.aspx?cp-documentid=4835390

Written by csirindia

January 24, 2011 at 8:11 pm

Posted in IMTECH

Cheaper clot busting drug from next fiscal

27 November 2010

CHANDIGARH: Come 2011-12, and India will roll out a blood clot busting injection for domestic and global markets at a much lower rate than its market price now. It will not only cost at least Rs 10,000 less, but also rule out bleeding problems — a common drug side-effect now.

Chandigarh-based Institute of Microbial Technology (Imtech) has made it possible to cost-cut expenditures and already filed two patents.

“This third generation drug is clot-specific…. prevents bleeding and targets only the affected area,” said Dr Girish Sahni, Imtech director and leader of the team which developed the drug.

The institute has inked an Rs 750-crore deal with New Jersey-based company for preclinical trials. “We have licensed this product to Nostrum, which will conduct trials and market it. We will get a royalty of 2.5% of the product cost,” said Girish.

Imtech had developed streptokinase (clot dissolver) in India in 2002. It was subsequently developed as first and second generation drug by 2009. The fourth generation drug will prevent re-occurrence of clot. “What it implies is that the drug can stay for some more time than the present 15-20 minute span and effectively work at the clot site without causing much toxicity,” he revealed.

Read more: http://timesofindia.indiatimes.com/city/chandigarh/Cheaper-clot-busting-drug-from-next-fiscal/articleshow/6998672.cms#ixzz16SE6Cec0

Written by csirindia

November 27, 2010 at 10:06 am

Posted in IMTECH

US firm to market molecules developed by IMTECH

27 November 2010

CHANDIGARH: Nostrum Pharmaceuticals, the US, has obtained the worldwide licence to develop and commercialise the third and fourth generation thrombolytic molecules developed by city-based Institute of Microbial Technology (IMTECH).

The technology has been transferred by IMTECH as part of a 150-million US dollars deal in milestone payments and royalties.

The agreement was signed in New Delhi in the presence of Union Minister of Science and Technology Kapil Sibal and Prof Samir K Brahmachari, Director General, Council for Scientific and Industrial Research.

In the recent past, IMTECH has developed safe, low-cost clot busters that have received a good response from the medical fraternity. These were developed after a long research by IMTECH director Dr Girish Sahni and his team. Dr Sahni said the fourth generation clot-busters also prevent re-occlusion.

Source: http://www.indianexpress.com/news/us-firm-to-market-molecules-developed-by-imtech/716890/

Written by csirindia

November 27, 2010 at 10:05 am

Posted in IMTECH

Nostrum Pharmaceuticals, LLC Licenses Clinical Development and Worldwide Commercialization Rights From IMTECH, India, for Novel, Next-Generation Thrombolytics With Clot Specific Activation and Re-occlusion Prevention Properties

24 November 2010

NEW BRUNSWICK, N.J: Nostrum Pharmaceuticals, LLC (“Nostrum”), a privately held pharmaceuticals company based in New Brunswick, New Jersey, announced today its licensing agreement with Institute of Microbial Technology (“IMTECH”), Chandigarh, India, a research institute under Council of Scientific and Industrial Research (“CSIR”), a Government of India organization.  Pursuant to such agreement, Nostrum will in-license next generation thrombolytics from IMTECH for clinical development and worldwide commercialization.

Nirmal Mulye, Ph.D., President of Nostrum, said, “These novel, next generation thrombolytics are clot specific plasminogen activator proteins, and each one of these molecules has a uniquely different value-added properties such as longer half-life in blood circulation and re-occlusion prevention during heart attack.  Moreover, these unique properties of the molecules will help to effectively mitigate a number of systemic side effects, such as bleeding, usually associated with the prevalent thrombolytic protein molecules in the market today.”  Dr. Mulye further said, “Our collaboration with CSIR is an example of successful public-private partnership.  This is our third collaboration with IMTECH/ CSIR.  Clearly they have been developing world-class technologies and setting an example of pursuing commercially viable innovations.”

These new molecules were invented at IMTECH in the laboratory headed by Girish Sahni, Ph.D., who is also the director of IMTECH.  Dr. Sahni said, “Re-occlusion of the blood vessel after thrombolytics treatment remains one of the main cause for patient death after the heart attack and continues to be both a practical and scientific challenge to reckon with.”  Dr. Sahni added, “My group at IMTECH had been working for a very long time to come up with an approach that will resolve the issue of blood vessel re-occlusion after thrombolytics treatment.  I am glad that one of our new thrombolytic molecules has shown that promise in the laboratory experiments.  Based on these results we are confident that it will develop into a world class drug with a most sought after property of not only clot specificity of activation but also re-occlusion prevention.”  Dr. Sahni further added, “Collaborating with Nostrum over the years has been a very fulfilling experience.  They have demonstrated a true commitment to take forward our collaborations as seen by the remarkable pace at which they have taken forward the development of our first thrombolytic Clot Specific Streptokinase (CSSK).”…..

Read more: http://www.sunherald.com/2010/11/24/2666186/nostrum-pharmaceuticals-llc-licenses.html#ixzz16GJTZG22

Written by csirindia

November 25, 2010 at 9:12 am

Posted in IMTECH